Safety studies of the intraperitoneal injection of E1A-liposome complex in mice

Gene Therapy

Volumn 4, Issue 3, 1997, Pages 238-243

  Xing, X ^a   Liu, V ^a   Xia, W ^a   Stephens, L C ^a   Huang, L ^b   Lopez Berestein, G ^a   Hung, M C ^a,c  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^c Box 79 ^*  (United States)

Author keywords

E1A liposome; Intraperitoneal injection; Toxicity

Indexed keywords

LIPOSOME; RECOMBINANT DNA; VIRUS PROTEIN;

ADENOVIRUS 5; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; FEMALE; GENE TRANSFER; HEMATOLOGICAL PARAMETERS; KIDNEY FUNCTION; LIVER FUNCTION; MOUSE; NONHUMAN; PRIORITY JOURNAL; SAFETY;

EID: 0030892609     PISSN: 09697128     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.gt.3300376     Document Type: Article

References (27)

1. Slamon DJ et al. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987, 235: 177-182.
2. Slamon DJ et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 1989; 244: 707-712.
3. Van de Vijver M et al. Amplification of the neu (c-erbB-2) oncogene in human mammary tumors is relatively frequent and is often accompanied by amplification of the linked c-erbA oncogene. Mol Cell Biol 1987; 7: 2019-2023.
4. Berchuck A et al. Overexpression of HER-2/neu is associated with poor survival in advanced epithelial ovarian cancer. Cancer Res 1990; 50: 4087-4091.
5. Yu D, Scorsone K, Hung M-C. Adenovirus type 5 E1A gene products act as transformation suppressors of the neu oncogene. Mol Cell Biol 1991; 11: 1745-1750.
6. Matin A, Hung M-C. Negative regulation of the neu promoter by the SV40 large T antigen. Cell Growth Differ 1993; 4: 1051-1056.
7. Zhang Y, Yu D, Xia W, Hung M-C. HER-2/neu-targeting cancer therapy via adenovirus-mediated E1A delivery in an animal model. Oncogene 1995; 10: 1947-1954.
8. Hung M-C et al. HER-2/neu-targeting gene therapy - a review. Gene 1995, 159: 65-71.
9. Xing X et al. Mutant SV40 Large T as a therapeutic agent for HER-2/new-overexpressing ovarian cancer. Cancer Gene Ther 1996; 3: 168-174.
10. Yu D et al. Liposome-mediated E1A gene transfer as therapy for ovarian cancers that overexpress HER-2/neu. Oncogene 1995; 11: 1383-1388.
11. Tooze J (ed. ). DNA tumor viruses. Molecular Biology of Tumor Viruses, 2nd edn. Cold Spring Harbor Laboratory: Cold Spring Harbor, NY, 1981, pp 451-474.
12. Yu D et al. Transcriptional repression of the neu protooncogene by the Adenovirus 5 E1A gene products. Proc Natl Acad Sci USA 1990; 87: 4499-4503.
13. Yan D-H, Chang L-S, Hung M-C. Repressed expression of the HER-2/neu/c-erbB-2 proto-oncogene by the adenovirus E1A gene products. Oncogene 1991; 6: 343-345.
14. Yu D et al. Enhanced c-erbB-2/neu expression in human ovarian cancer cells correlates with more severe malignancy that can be suppressed by E1A Cancer Res 1993, 53: 891-898.
15. Denise L et al. Cancer gene therapy using plasmid DNA: pharmacokinetic study of DNA following injection in mice. Hum Gene Ther 1995; 6: 553-564.
16. Stewart MJ et al. Gene transfer in vivo with DNA-liposome complexes: safety and acute toxicity in mice. Hum Gene Ther 1992; 3: 267-275.
17. Parker SE et al. Cancer gene therapy using plasmid DNA: safety evaluation in rodents and non-human primates. Hum Gene Ther 1995; 6. 575-590.
18. Nable GJ et al. Direct gene transfer with DNA-liposome complexes in melanoma: expression, biologic activity, and lack of toxicity in humans. Proc Natl Acad Sci USA 1993; 90: 11307-11311.
19. Canonico AE et al. No lung toxicity after repeated aerosol or intravenous delivery of plasmid-cationic liposome complexes. J Appl Physiol 1994; 77: 415-419.
20. Hong S et al. Safety and short-term toxicity of a novel cationic lipid formulation for human gene therapy. Hum Gene Ther 1993; 4: 781-788.
21. Kojima H, Ohishi H, Takamori M, Yagi K. Cationic multilamellar liposome-mediated gene transfer into primary myoblasts. Biochem Biophys Res Commun 1995; 207: 8-12.
22. Hara T et al. Receptor-mediated transfer of pSV2CAT DNA to a human hepatoblastoma cell line HepG2 using asialofetuin-labeled cationic liposome. Gene 1995; 159: 167-174.
23. Logan JJ et al. Cationic lipids for receptor gene and CFTR transfer to rat pulmonary epithelium. Gene Therapy 1995; 2: 38-49.
24. Gao X, Huang L. A novel cationic liposome reagent for efficient transfection of mammalian cells. Biochem Biophys Res Commun 1991; 179: 280-285.
25. Lloyd WE. Safety Evaluation of Drugs and Chemicals. Hemishere Publishing Corporation: Washington DC, 1986.
26. Freireich EJ et al. Quantitative comparison of toxicity of anticancer agents on mouse, rat, hamster, dog, monkey, and man Cancer Chemother Rep 1966; 50: 219-244.
27. Altman PL and The Biology Databook Editorial Board. Pathology of Laboratory Mice and Rats. FASEB and Pergamon Inforline: Bethesda, MD, 1985.